- Home
- / Promontory Therapeutics
Promontory Therapeutics
Total Funding
$35 M
Promontory Therapeutics Summary
Company Summary
- Overview
- Promontory Therapeutics (formerly Phosplatin Therapeutics) is a pharmaceutical company developing anti-cancer agents for the oncology industry. It offers PT-112, a well-tolerated immunogenic cell death (ICD) inducer.
- Type
- Private
- Status
- Active
- Founded
- 2010
- HQ
- New York, NY, US | view all locations
- Website
- https://promontorytx.com/
- Cybersecurity rating
Table of Contents
Key People
Robert E. Fallon, President & CEO
Tyler Ames, Senior Vice President, Research & Development
Matthew R. Price, Executive Vice President & COO
LocationsView all
1 location detected
New York, NY HQ
United States
1350 6th Ave 23rd fl